Reported Earlier, Eisai and Biogen Launch Alzheimer's Drug LEQEMBI in China
Portfolio Pulse from Benzinga Newsdesk
Eisai and Biogen have launched their Alzheimer's drug LEQEMBI in China. The drug, which targets amyloid-beta aggregates, is the first approved treatment to reduce disease progression and cognitive decline. Eisai is leading the distribution and awareness efforts in China, collaborating with health insurance companies and online health platforms.
June 28, 2024 | 7:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen, in collaboration with Eisai, has launched the Alzheimer's drug LEQEMBI in China. This marks the third country where the drug is available, following the US and Japan. The drug aims to reduce disease progression and cognitive decline in early Alzheimer's patients.
The launch of LEQEMBI in China represents a significant market expansion for Biogen, potentially increasing revenue and market share. The drug's unique mechanism and approval in a large market like China are likely to positively impact Biogen's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 80